Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Pilot Study of Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06398457
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:15.482869+00:00
Published At
2025-09-26T00:00:00+00:00
Record Updated At
2025-09-26
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Hematologic Malignancy", "Bone Marrow Transplant Rejection", "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndromes (MDS)", "Acute Lymphoblastic Leukemia (ALL), Adult", "Multiple Myeloma", "Aplastic Anemia", "Lymphoma", "Non Hodgkin Lymphoma", "Hodgkin Lymphoma", "Chronic Myeloid Leukemia", "Myelofibrosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-09-26"
protocolSection.identificationModule.nctId
"NCT06398457"
protocolSection.identificationModule.officialTitle
"A Pilot Study of Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["EARLY_PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Hematologic Malignancy (protocolSection.conditionsModule.conditions)
  • Bone Marrow Transplant Rejection (protocolSection.conditionsModule.conditions)
  • Acute Myeloid Leukemia (AML) (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndromes (MDS) (protocolSection.conditionsModule.conditions)
  • Acute Lymphoblastic Leukemia (ALL), Adult (protocolSection.conditionsModule.conditions)
  • Multiple Myeloma (protocolSection.conditionsModule.conditions)
  • Aplastic Anemia (protocolSection.conditionsModule.conditions)
  • Lymphoma (protocolSection.conditionsModule.conditions)
  • Non Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Chronic Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Myelofibrosis (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.